Injection-Site Reaction to Brodalumab in a Psoriasis Patient: Report of Clinicopathological Findings

Am J Dermatopathol. 2022 Jul 1;44(7):538-539. doi: 10.1097/DAD.0000000000002170. Epub 2022 Mar 1.

Authors

I-Hsuan Huang¹, Yi-Wei Huang^{1

2}, Jau-Yu Liau³, Tsen-Fang Tsai^{1

2}

Affiliations

¹ Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan.
² Department of Dermatology, National Taiwan University College of Medicine, Taipei, Taiwan.
³ Department of Pathology, National Taiwan University Hospital.

PMID: 35234190
DOI: 10.1097/DAD.0000000000002170

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Humans
Psoriasis* / drug therapy
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
brodalumab